GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Jiudian Pharmaceutical Co Ltd (SZSE:300705) » Definitions » Return-on-Tangible-Asset

Hunan Jiudian Pharmaceutical Co (SZSE:300705) Return-on-Tangible-Asset : 15.34% (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Hunan Jiudian Pharmaceutical Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Hunan Jiudian Pharmaceutical Co's annualized Net Income for the quarter that ended in Mar. 2025 was ¥503 Mil. Hunan Jiudian Pharmaceutical Co's average total tangible assets for the quarter that ended in Mar. 2025 was ¥3,279 Mil. Therefore, Hunan Jiudian Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was 15.34%.

The historical rank and industry rank for Hunan Jiudian Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:

SZSE:300705' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.77   Med: 14.4   Max: 17.13
Current: 16.57

During the past 12 years, Hunan Jiudian Pharmaceutical Co's highest Return-on-Tangible-Asset was 17.13%. The lowest was 5.77%. And the median was 14.40%.

SZSE:300705's Return-on-Tangible-Asset is ranked better than
92.37% of 1022 companies
in the Drug Manufacturers industry
Industry Median: 2.68 vs SZSE:300705: 16.57

Hunan Jiudian Pharmaceutical Co Return-on-Tangible-Asset Historical Data

The historical data trend for Hunan Jiudian Pharmaceutical Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Jiudian Pharmaceutical Co Return-on-Tangible-Asset Chart

Hunan Jiudian Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.84 14.87 13.95 14.85 17.13

Hunan Jiudian Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.94 21.86 21.87 7.92 15.34

Competitive Comparison of Hunan Jiudian Pharmaceutical Co's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Jiudian Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Jiudian Pharmaceutical Co's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Jiudian Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Hunan Jiudian Pharmaceutical Co's Return-on-Tangible-Asset falls into.


;
;

Hunan Jiudian Pharmaceutical Co Return-on-Tangible-Asset Calculation

Hunan Jiudian Pharmaceutical Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=512.377/( (2758.968+3223.024)/ 2 )
=512.377/2990.996
=17.13 %

Hunan Jiudian Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=503.104/( (3223.024+3335.229)/ 2 )
=503.104/3279.1265
=15.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Hunan Jiudian Pharmaceutical Co  (SZSE:300705) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Hunan Jiudian Pharmaceutical Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Hunan Jiudian Pharmaceutical Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Hunan Jiudian Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.1 Health Avenue, Hunan Liuyang Bio Pharmaceutical Park, Hunan, Changsha, CHN, 410329
Hunan Jiudian Pharmaceutical Co Ltd is a China-based pharmaceutical company specializing in research and development, manufacturing of pharmaceutical products, solid and liquid oral preparations and herbal extract products. It manufactures dirithromycin, levodropropizine and levocetirizine hydrochloride in China. The group's products include active pharmaceutical ingredients, herbal extracts, intermediaries, excipients and finished products.
Executives
Xiong Ying Executives
Zhu Zhi Hong Director
Duan Bin Supervisors
Liang Sheng Hua Supervisors
Zheng Xia Hui Directors, executives
Duan Li Xin Director
Zhu Zhi Yun Director
Li Min Secretary Dong
Fan Peng Yun Executives

Hunan Jiudian Pharmaceutical Co Headlines

No Headlines